Custom cancer vaccine trial uses 'Quantum' tech to target tumors
NCT ID NCT07316361
Summary
This early-phase trial is testing a personalized vaccine for people with high-risk or recurrent endometrial cancer. The vaccine is custom-made for each patient based on the unique genetic markers of their tumor, with the goal of training their immune system to fight the cancer. All 40 participants will receive the vaccine alongside their doctor's choice of standard cancer treatments to see if it is safe and can trigger an immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenea Pharmaceuticals Ltd & Interbalkan Medical Center - International Oncology Center
Thessaloniki, Thessaloniki, 54622, Greece
Conditions
Explore the condition pages connected to this study.